Trials / Conditions / Recurrent Vulvovaginal Candidiasis

Recurrent Vulvovaginal Candidiasis

13 registered clinical trials studyying Recurrent Vulvovaginal Candidiasis.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvova NCT06190509	LimmaTech Biologics AG	Phase 1 / Phase 2
Completed	Blue Light Emitting Diode Therapy on Vulvovaginal Candidiasis NCT05795491	Cairo University	N/A
Unknown	A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal NCT05074602	Jiangsu HengRui Medicine Co., Ltd.	Phase 3
Unknown	Effect of a Lactobacillus Strain on the Prevention of Recurrent Vaginal Candidiasis NCT04639544	Biosearch S.A.	N/A
Completed	Study of Lactobacillus in Adjuvant Treatment of RVVC NCT04699240	Peking University Shenzhen Hospital	Phase 4
Completed	Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis NCT04029116	Scynexis, Inc.	Phase 3
Unknown	A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) NCT04734405	ProFem GmbH	Phase 2 / Phase 3
Completed	Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections NCT03840616	Mycovia Pharmaceuticals Inc.	Phase 3
Completed	A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeas NCT03561701	Mycovia Pharmaceuticals Inc.	Phase 3
Completed	A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infectio NCT03562156	Mycovia Pharmaceuticals Inc.	Phase 3
Completed	Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractor NCT03059992	Scynexis, Inc.	Phase 3
Completed	A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infect NCT02267382	Viamet	Phase 2
Completed	Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection NCT01067131	Pevion Biotech Ltd	Phase 1